This job has expired

Postdoctoral Fellow - Cancer Biology and Immunotherapy

Employer
Nationwide Children's Hospital
Location
Riverlea, Ohio, US
Salary
Competitive
Closing date
Dec 10, 2022

View more

Sector
Academic / Research
Field
Conservation science
Discipline
Biology
Salary Type
Salary
Employment Type
Fellowship
You need to sign in or create an account to save a job.
Postdoctoral (PhD and/or MD) position available at Nationwide Children's Hospital and The Ohio State University in Childhood Cancer to study:

* Tumorigenesis mechanisms underlying neurofibromatosis-associated tumors
* Pediatric sarcomas
* Evaluate novel targeted molecules and immunotherapies.

Qualified candidates should have PhD training in Cancer Biology, Biochemistry, Molecular Biology, or related field. In addition, candidates should have knowledge in molecular signaling and translational research. Interested individuals should send CV and references to:

Dr. Long-Sheng Chang
Center for Childhood Cancer Research
Abigail Wexner Research Institute at Nationwide Children's Hospital
E-mail: Long-Sheng.Chang@nationwidechildrens.org or chang.22@osu.edu

Recent publications :
Chang L-S, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, et al. Targeting protein translation by rocaglamide and didesmethylrocaglamide to treat MPNST and other sarcomas. Mol Cancer Ther. 2020;19:731-741. PMID: 31848295

Agarwal G, Chang L-S, Soejarto DD, Kinghorn AD. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Med. 2021;87:937-948. PMID: 33784769

Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, et al. Brigatinib causes tumor shrinkage in both NF2 -deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021;16:e0252048. PMID: 34264955

Amaravathi A*, Oblinger JL*, Welling DB, Kinghorn AD, Chang L-S. Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021;11:698192. PMID: 34604034 (*Co-first authors)

Welling DB*, Collier KA*, Burns SS*, Oblinger JL, Shu E, Miles-Markley B, et al. Early phase clinical studies of AR-42, a pan-histone deacetylase inhibitor, in patients with neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Submitted to Laryngoscope Investig Otolaryngol. 2021;6:1008-1019. PMID:34667843 (*Co-first authors)

Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S, et al. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy . Sci Adv. 2022;8:eabo5442. Doi: 10.1126/sciadv.abo5442. Epub 2022 Nov 2. PMID: 36322658

Bhattacharyya S, Oblinger JL, Beauchamp RL, Yin Z, Erdin S, Koundinya P, et al. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma. Neuro-Oncol. 2022;In Press.
You need to sign in or create an account to save a job.

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert